Standard Surfactants Limited (STDSFAC.BO) Stock Competitors & Peer Comparison
See (STDSFAC.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Household & Personal Products Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| STDSFAC.BO | ₹49.30 | +3.31% | 407.3M | N/A | N/A | N/A |
| HINDUNILVR.BO | ₹2,195.90 | -1.02% | 5.2T | 47.49 | ₹46.24 | +1.96% |
| HINDUNILVR.NS | ₹2,194.60 | -1.08% | 5.2T | 48.42 | ₹45.32 | +1.96% |
| MARICO.BO | ₹816.80 | -0.44% | 1.1T | 61.88 | ₹13.20 | +0.86% |
| MARICO.NS | ₹817.05 | -0.45% | 1.1T | 60.17 | ₹13.58 | +0.86% |
| GODREJCP.BO | ₹1,000.40 | -0.79% | 1T | 56.17 | ₹17.81 | +2.00% |
| GODREJCP.NS | ₹1,000.60 | -0.85% | 1T | 54.95 | ₹18.21 | +2.00% |
| DABUR.BO | ₹423.65 | -1.20% | 751.4B | 40.85 | ₹10.37 | +1.89% |
| DABUR.NS | ₹423.50 | -1.21% | 751.3B | 39.69 | ₹10.67 | +1.89% |
| COLPAL.BO | ₹1,997.95 | -1.41% | 543.6B | 40.87 | ₹48.88 | +2.40% |
Stock Comparison
STDSFAC.BO vs HINDUNILVR.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, HINDUNILVR.BO has a market cap of 5.2T. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while HINDUNILVR.BO trades at ₹2,195.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas HINDUNILVR.BO's P/E ratio is 47.49. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to HINDUNILVR.BO's ROE of +0.31%. Regarding short-term risk, STDSFAC.BO is more volatile compared to HINDUNILVR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check HINDUNILVR.BO's competition here
STDSFAC.BO vs HINDUNILVR.NS Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, HINDUNILVR.NS has a market cap of 5.2T. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while HINDUNILVR.NS trades at ₹2,194.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas HINDUNILVR.NS's P/E ratio is 48.42. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to HINDUNILVR.NS's ROE of +0.31%. Regarding short-term risk, STDSFAC.BO is more volatile compared to HINDUNILVR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check HINDUNILVR.NS's competition here
STDSFAC.BO vs MARICO.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, MARICO.BO has a market cap of 1.1T. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while MARICO.BO trades at ₹816.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas MARICO.BO's P/E ratio is 61.88. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to MARICO.BO's ROE of +0.43%. Regarding short-term risk, STDSFAC.BO is more volatile compared to MARICO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check MARICO.BO's competition here
STDSFAC.BO vs MARICO.NS Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, MARICO.NS has a market cap of 1.1T. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while MARICO.NS trades at ₹817.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas MARICO.NS's P/E ratio is 60.17. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to MARICO.NS's ROE of +0.43%. Regarding short-term risk, STDSFAC.BO is more volatile compared to MARICO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check MARICO.NS's competition here
STDSFAC.BO vs GODREJCP.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, GODREJCP.BO has a market cap of 1T. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while GODREJCP.BO trades at ₹1,000.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas GODREJCP.BO's P/E ratio is 56.17. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to GODREJCP.BO's ROE of +0.15%. Regarding short-term risk, STDSFAC.BO is more volatile compared to GODREJCP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check GODREJCP.BO's competition here
STDSFAC.BO vs GODREJCP.NS Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, GODREJCP.NS has a market cap of 1T. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while GODREJCP.NS trades at ₹1,000.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas GODREJCP.NS's P/E ratio is 54.95. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to GODREJCP.NS's ROE of +0.15%. Regarding short-term risk, STDSFAC.BO is more volatile compared to GODREJCP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check GODREJCP.NS's competition here
STDSFAC.BO vs DABUR.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, DABUR.BO has a market cap of 751.4B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while DABUR.BO trades at ₹423.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas DABUR.BO's P/E ratio is 40.85. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to DABUR.BO's ROE of +0.17%. Regarding short-term risk, STDSFAC.BO is more volatile compared to DABUR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check DABUR.BO's competition here
STDSFAC.BO vs DABUR.NS Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, DABUR.NS has a market cap of 751.3B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while DABUR.NS trades at ₹423.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas DABUR.NS's P/E ratio is 39.69. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to DABUR.NS's ROE of +0.17%. Regarding short-term risk, STDSFAC.BO is more volatile compared to DABUR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check DABUR.NS's competition here
STDSFAC.BO vs COLPAL.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, COLPAL.BO has a market cap of 543.6B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while COLPAL.BO trades at ₹1,997.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas COLPAL.BO's P/E ratio is 40.87. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to COLPAL.BO's ROE of +0.82%. Regarding short-term risk, STDSFAC.BO is more volatile compared to COLPAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check COLPAL.BO's competition here
STDSFAC.BO vs COLPAL.NS Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, COLPAL.NS has a market cap of 543.4B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while COLPAL.NS trades at ₹1,997.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas COLPAL.NS's P/E ratio is 41.06. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to COLPAL.NS's ROE of +0.82%. Regarding short-term risk, STDSFAC.BO is more volatile compared to COLPAL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check COLPAL.NS's competition here
STDSFAC.BO vs PGHH.NS Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, PGHH.NS has a market cap of 301.1B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while PGHH.NS trades at ₹9,274.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas PGHH.NS's P/E ratio is 35.11. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to PGHH.NS's ROE of +1.08%. Regarding short-term risk, STDSFAC.BO is less volatile compared to PGHH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for STDSFAC.BO.Check PGHH.NS's competition here
STDSFAC.BO vs PGHH.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, PGHH.BO has a market cap of 300.8B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while PGHH.BO trades at ₹9,269.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas PGHH.BO's P/E ratio is 41.88. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to PGHH.BO's ROE of +1.08%. Regarding short-term risk, STDSFAC.BO is less volatile compared to PGHH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for STDSFAC.BO.Check PGHH.BO's competition here
STDSFAC.BO vs GILLETTE.NS Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, GILLETTE.NS has a market cap of 255.1B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while GILLETTE.NS trades at ₹7,828.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas GILLETTE.NS's P/E ratio is 47.86. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to GILLETTE.NS's ROE of +0.63%. Regarding short-term risk, STDSFAC.BO is more volatile compared to GILLETTE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check GILLETTE.NS's competition here
STDSFAC.BO vs GILLETTE.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, GILLETTE.BO has a market cap of 254.9B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while GILLETTE.BO trades at ₹7,825.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas GILLETTE.BO's P/E ratio is 47.88. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to GILLETTE.BO's ROE of +0.63%. Regarding short-term risk, STDSFAC.BO is more volatile compared to GILLETTE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check GILLETTE.BO's competition here
STDSFAC.BO vs CUPID.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, CUPID.BO has a market cap of 238.4B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while CUPID.BO trades at ₹176.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas CUPID.BO's P/E ratio is 223.54. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to CUPID.BO's ROE of +0.29%. Regarding short-term risk, STDSFAC.BO is less volatile compared to CUPID.BO. This indicates potentially lower risk in terms of short-term price fluctuations for STDSFAC.BO.Check CUPID.BO's competition here
STDSFAC.BO vs CUPID.NS Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, CUPID.NS has a market cap of 237.9B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while CUPID.NS trades at ₹176.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas CUPID.NS's P/E ratio is 223.95. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to CUPID.NS's ROE of +0.29%. Regarding short-term risk, STDSFAC.BO is less volatile compared to CUPID.NS. This indicates potentially lower risk in terms of short-term price fluctuations for STDSFAC.BO.Check CUPID.NS's competition here
STDSFAC.BO vs EMAMILTD.NS Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, EMAMILTD.NS has a market cap of 180.5B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while EMAMILTD.NS trades at ₹413.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas EMAMILTD.NS's P/E ratio is 23.27. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to EMAMILTD.NS's ROE of +0.28%. Regarding short-term risk, STDSFAC.BO is less volatile compared to EMAMILTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for STDSFAC.BO.Check EMAMILTD.NS's competition here
STDSFAC.BO vs EMAMILTD.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, EMAMILTD.BO has a market cap of 180.2B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while EMAMILTD.BO trades at ₹413.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas EMAMILTD.BO's P/E ratio is 23.23. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to EMAMILTD.BO's ROE of +0.28%. Regarding short-term risk, STDSFAC.BO is less volatile compared to EMAMILTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for STDSFAC.BO.Check EMAMILTD.BO's competition here
STDSFAC.BO vs HONASA.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, HONASA.BO has a market cap of 135.9B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while HONASA.BO trades at ₹417.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas HONASA.BO's P/E ratio is 68.13. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to HONASA.BO's ROE of +0.16%. Regarding short-term risk, STDSFAC.BO is less volatile compared to HONASA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for STDSFAC.BO.Check HONASA.BO's competition here
STDSFAC.BO vs HONASA.NS Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, HONASA.NS has a market cap of 135.8B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while HONASA.NS trades at ₹417.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas HONASA.NS's P/E ratio is 68.09. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to HONASA.NS's ROE of +0.16%. Regarding short-term risk, STDSFAC.BO is less volatile compared to HONASA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for STDSFAC.BO.Check HONASA.NS's competition here
STDSFAC.BO vs BAJAJCON.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, BAJAJCON.BO has a market cap of 82B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while BAJAJCON.BO trades at ₹625.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas BAJAJCON.BO's P/E ratio is 43.94. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to BAJAJCON.BO's ROE of +0.26%. Regarding short-term risk, STDSFAC.BO is more volatile compared to BAJAJCON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check BAJAJCON.BO's competition here
STDSFAC.BO vs BAJAJCON.NS Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, BAJAJCON.NS has a market cap of 82B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while BAJAJCON.NS trades at ₹625.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas BAJAJCON.NS's P/E ratio is 43.94. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to BAJAJCON.NS's ROE of +0.26%. Regarding short-term risk, STDSFAC.BO is more volatile compared to BAJAJCON.NS. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check BAJAJCON.NS's competition here
STDSFAC.BO vs JYOTHYLAB.NS Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, JYOTHYLAB.NS has a market cap of 74.9B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while JYOTHYLAB.NS trades at ₹202.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas JYOTHYLAB.NS's P/E ratio is 21.91. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to JYOTHYLAB.NS's ROE of +0.19%. Regarding short-term risk, STDSFAC.BO is more volatile compared to JYOTHYLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check JYOTHYLAB.NS's competition here
STDSFAC.BO vs JYOTHYLAB.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, JYOTHYLAB.BO has a market cap of 74.9B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while JYOTHYLAB.BO trades at ₹202.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas JYOTHYLAB.BO's P/E ratio is 21.91. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to JYOTHYLAB.BO's ROE of +0.19%. Regarding short-term risk, STDSFAC.BO is more volatile compared to JYOTHYLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check JYOTHYLAB.BO's competition here
STDSFAC.BO vs ALLTIME.NS Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, ALLTIME.NS has a market cap of 15.7B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while ALLTIME.NS trades at ₹240.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas ALLTIME.NS's P/E ratio is 41.58. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to ALLTIME.NS's ROE of +0.07%. Regarding short-term risk, STDSFAC.BO is less volatile compared to ALLTIME.NS. This indicates potentially lower risk in terms of short-term price fluctuations for STDSFAC.BO.Check ALLTIME.NS's competition here
STDSFAC.BO vs BCLIND.NS Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, BCLIND.NS has a market cap of 11B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while BCLIND.NS trades at ₹37.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas BCLIND.NS's P/E ratio is 9.53. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to BCLIND.NS's ROE of +0.14%. Regarding short-term risk, STDSFAC.BO is more volatile compared to BCLIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check BCLIND.NS's competition here
STDSFAC.BO vs KAYA.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, KAYA.BO has a market cap of 3.9B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while KAYA.BO trades at ₹256.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas KAYA.BO's P/E ratio is -3.85. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to KAYA.BO's ROE of +0.73%. Regarding short-term risk, STDSFAC.BO is less volatile compared to KAYA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for STDSFAC.BO.Check KAYA.BO's competition here
STDSFAC.BO vs KAYA.NS Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, KAYA.NS has a market cap of 3.8B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while KAYA.NS trades at ₹252.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas KAYA.NS's P/E ratio is -3.79. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to KAYA.NS's ROE of +0.73%. Regarding short-term risk, STDSFAC.BO is more volatile compared to KAYA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check KAYA.NS's competition here
STDSFAC.BO vs ADORMUL.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, ADORMUL.BO has a market cap of 1.3B. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while ADORMUL.BO trades at ₹135.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas ADORMUL.BO's P/E ratio is -29.80. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to ADORMUL.BO's ROE of -0.32%. Regarding short-term risk, STDSFAC.BO is less volatile compared to ADORMUL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for STDSFAC.BO.Check ADORMUL.BO's competition here
STDSFAC.BO vs PCCOSMA.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, PCCOSMA.BO has a market cap of 797.6M. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while PCCOSMA.BO trades at ₹301.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas PCCOSMA.BO's P/E ratio is 9.57. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to PCCOSMA.BO's ROE of +0.16%. Regarding short-term risk, STDSFAC.BO is less volatile compared to PCCOSMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for STDSFAC.BO.Check PCCOSMA.BO's competition here
STDSFAC.BO vs JHS.NS Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, JHS.NS has a market cap of 698.4M. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while JHS.NS trades at ₹7.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas JHS.NS's P/E ratio is -36.32. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to JHS.NS's ROE of -0.01%. Regarding short-term risk, STDSFAC.BO is less volatile compared to JHS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for STDSFAC.BO.Check JHS.NS's competition here
STDSFAC.BO vs JHS.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, JHS.BO has a market cap of 683.9M. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while JHS.BO trades at ₹7.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas JHS.BO's P/E ratio is -8.75. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to JHS.BO's ROE of -0.01%. Regarding short-term risk, STDSFAC.BO is less volatile compared to JHS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for STDSFAC.BO.Check JHS.BO's competition here
STDSFAC.BO vs AMBICAAGAR.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, AMBICAAGAR.BO has a market cap of 419.1M. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while AMBICAAGAR.BO trades at ₹24.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas AMBICAAGAR.BO's P/E ratio is 82.97. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to AMBICAAGAR.BO's ROE of +0.03%. Regarding short-term risk, STDSFAC.BO is less volatile compared to AMBICAAGAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for STDSFAC.BO.Check AMBICAAGAR.BO's competition here
STDSFAC.BO vs AMBICAAGAR.NS Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, AMBICAAGAR.NS has a market cap of 417.2M. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while AMBICAAGAR.NS trades at ₹24.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas AMBICAAGAR.NS's P/E ratio is 12.08. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to AMBICAAGAR.NS's ROE of +0.03%. Regarding short-term risk, STDSFAC.BO is less volatile compared to AMBICAAGAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for STDSFAC.BO.Check AMBICAAGAR.NS's competition here
STDSFAC.BO vs NKIND.NS Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, NKIND.NS has a market cap of 378.6M. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while NKIND.NS trades at ₹63.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas NKIND.NS's P/E ratio is -10.45. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to NKIND.NS's ROE of +0.01%. Regarding short-term risk, STDSFAC.BO is less volatile compared to NKIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for STDSFAC.BO.Check NKIND.NS's competition here
STDSFAC.BO vs NKIND.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, NKIND.BO has a market cap of 378.6M. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while NKIND.BO trades at ₹62.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas NKIND.BO's P/E ratio is -10.28. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to NKIND.BO's ROE of +0.01%. Regarding short-term risk, STDSFAC.BO is less volatile compared to NKIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for STDSFAC.BO.Check NKIND.BO's competition here
STDSFAC.BO vs NUWAY.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, NUWAY.BO has a market cap of 354.6M. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while NUWAY.BO trades at ₹37.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas NUWAY.BO's P/E ratio is 14.40. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to NUWAY.BO's ROE of N/A. Regarding short-term risk, STDSFAC.BO is more volatile compared to NUWAY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check NUWAY.BO's competition here
STDSFAC.BO vs PAOS.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, PAOS.BO has a market cap of 307.3M. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while PAOS.BO trades at ₹50.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas PAOS.BO's P/E ratio is -14.55. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to PAOS.BO's ROE of +0.13%. Regarding short-term risk, STDSFAC.BO is more volatile compared to PAOS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check PAOS.BO's competition here
STDSFAC.BO vs SATTVASUKU.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, SATTVASUKU.BO has a market cap of 287.7M. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while SATTVASUKU.BO trades at ₹0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas SATTVASUKU.BO's P/E ratio is -75.00. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to SATTVASUKU.BO's ROE of +0.09%. Regarding short-term risk, STDSFAC.BO is more volatile compared to SATTVASUKU.BO. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check SATTVASUKU.BO's competition here
STDSFAC.BO vs HIPOLIN.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, HIPOLIN.BO has a market cap of 224M. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while HIPOLIN.BO trades at ₹71.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas HIPOLIN.BO's P/E ratio is -29.08. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to HIPOLIN.BO's ROE of -0.09%. Regarding short-term risk, STDSFAC.BO is more volatile compared to HIPOLIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check HIPOLIN.BO's competition here
STDSFAC.BO vs PARMCOS-B.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, PARMCOS-B.BO has a market cap of 167.3M. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while PARMCOS-B.BO trades at ₹34.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas PARMCOS-B.BO's P/E ratio is 313.18. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to PARMCOS-B.BO's ROE of +0.00%. Regarding short-term risk, STDSFAC.BO is more volatile compared to PARMCOS-B.BO. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check PARMCOS-B.BO's competition here
STDSFAC.BO vs CORNE.BO Comparison June 2026
STDSFAC.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STDSFAC.BO stands at 407.3M. In comparison, CORNE.BO has a market cap of 48.2M. Regarding current trading prices, STDSFAC.BO is priced at ₹49.30, while CORNE.BO trades at ₹9.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STDSFAC.BO currently has a P/E ratio of N/A, whereas CORNE.BO's P/E ratio is -15.13. In terms of profitability, STDSFAC.BO's ROE is N/A, compared to CORNE.BO's ROE of +0.03%. Regarding short-term risk, STDSFAC.BO is more volatile compared to CORNE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for STDSFAC.BO.Check CORNE.BO's competition here